Wall Street analysts expect Natera, Inc. (NASDAQ:NTRA – Get Rating) to announce earnings per share (EPS) of ($1.46) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Natera’s earnings, with estimates ranging from ($1.52) to ($1.37). Natera reported earnings per share of ($1.32) during the same quarter last year, which would suggest a negative year-over-year growth rate of 10.6%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Natera will report full year earnings of ($5.82) per share for the current financial year, with EPS estimates ranging from ($5.94) to ($5.43). For the next financial year, analysts expect that the business will post earnings of ($4.90) per share, with EPS estimates ranging from ($5.53) to ($4.02). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Natera.
Natera (NASDAQ:NTRA – Get Rating) last announced its quarterly earnings data on Friday, May 6th. The medical research company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.50) by $0.05. Natera had a negative return on equity of 96.99% and a negative net margin of 81.90%. The business had revenue of $194.13 million during the quarter, compared to analyst estimates of $176.61 million. During the same period in the prior year, the company earned ($0.74) earnings per share. Natera’s revenue was up 27.5% compared to the same quarter last year.
In other news, Director Roelof Botha purchased 153,000 shares of the firm’s stock in a transaction on Wednesday, March 16th. The shares were bought at an average cost of $32.72 per share, with a total value of $5,006,160.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,147 shares of the firm’s stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $42.16, for a total transaction of $48,357.52. The disclosure for this sale can be found here. Insiders sold a total of 16,332 shares of company stock valued at $659,678 in the last quarter. Insiders own 10.27% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the business. Selective Wealth Management Inc. acquired a new stake in shares of Natera in the fourth quarter worth approximately $28,000. CENTRAL TRUST Co boosted its position in shares of Natera by 200.0% in the fourth quarter. CENTRAL TRUST Co now owns 300 shares of the medical research company’s stock worth $28,000 after acquiring an additional 200 shares during the last quarter. Industry Ventures L.L.C. acquired a new stake in shares of Natera in the fourth quarter worth approximately $30,000. CI Investments Inc. acquired a new stake in shares of Natera in the third quarter worth approximately $39,000. Finally, San Luis Wealth Advisors LLC acquired a new stake in shares of Natera in the first quarter worth approximately $34,000. 96.24% of the stock is currently owned by institutional investors.
Shares of Natera stock traded up $0.99 during trading hours on Friday, reaching $39.96. The company had a trading volume of 999,803 shares, compared to its average volume of 1,626,186. Natera has a one year low of $26.10 and a one year high of $129.09. The business has a fifty day simple moving average of $37.89 and a 200 day simple moving average of $65.44. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.24 and a quick ratio of 4.13. The firm has a market cap of $3.85 billion, a PE ratio of -6.80 and a beta of 1.24.
About Natera (Get Rating)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.